The objective of this study was to evaluate mechanisms of the synergy between high intensityfocused ultrasound (HIFU) and docetaxel and to determine the best sequence of chemotherapy administration in relation to HIFU treatment for obtaining optimum control of tumoral growth. A total of 15 days after s.c. implantation of the tumor, 52 Copenhagen rats studied were randomized in 4 groups of 13: controls, docetaxel alone (group 1), HIFU and docetaxel concomitant (group 2) and HIFU and docetaxel administered 24 h before treatment (group 3). The number of HIFU shots was calculated in order to cover 75% of the tumor volume. The effects of docetaxel, HIFU and their interaction on tumor volumes were analyzed using a linear regression. The distributions of the tumor volumes were significantly greater in the control group than in the group 1 (P ¼ 0.002) and than in both groups 2 and 3 (Po0.0001 and P ¼ 0.0001). These volumes were also significantly greater in group 1 than in both groups 2 and 3 and there was no difference between the groups 2 and 3. The tumor doubling times were 7.8 days for the group 1, 43.8 days for the group 2, 16.1 days for the group 3 and 5.9 days for the controls. The mechanism of the synergy between HIFU and docetaxel on the growth of Dunning tumors is apparently multifaceted. The results are encouraging because in the two groups of rats treated with the combination of HIFU and docetaxel, the percentage of complete remission was approximately 30%.
Introduction
High intensity-focused ultrasound (HIFU) is used in the clinical setting to treat localized prostate cancer in patients who are either not candidates for surgical treatment (because of their age or comorbidity) or they do not wish to be treated surgically or with radiotherapy. 1 With an actuarial 5-year disease-free survival rate at 66%, most authors still report 6-17% residual cancerous tissue in the patients treated. [2] [3] [4] The persistence of tumor cells after treatment is most often explained by the presence of a locally advanced understaged prostate cancer with extracapsular extensions, and given that the HIFU treatment is localized in the prostate these extraprostatic cells are therefore not destroyed. 5 From these diagnostic findings the importance was raised of adding chemotherapy to the HIFU treatment with the aim of destroying residual cells. The concept of combining HIFU and chemotherapy dates back to the beginning of the 1990s when studies proved that in vivo, this combination was synergic and superior to treatment with HIFU alone or chemotherapy alone. [6] [7] [8] [9] This was notably demonstrated with adriamycin on C 1300 neuroblastoma, doxorubicin and cyclophosphamide on Morris hepatoma or more recently with mitomycin on urothelial carcinoma of the urinary bladder. 10 In 2005, we demonstrated for the first time that this HIFU/chemotherapy synergic effect also exists with the combination of paclitaxel and estramustin phosphate on Dunning tumors implanted subcutaneously in Copenhagen rats. 5 We found that tumoral growth in the HIFU-alone and chemotherapy-alone arm was superimposable and statistically different from the HIFU/chemotherapy arm which seemed to be the optimal treatment. However the mechanisms of this synergy are not well understood. Two concepts might explain this phenomenon: the first is the belief that HIFU acts on tumor cells that are already weakened by chemotherapy administered 24 h before treatment; 5, 8 the second belief is that it is the concomitant application of HIFU and chemotherapy that allows better intracellular diffusion of the chemotherapy and therefore an accrued cytotoxicity. [6] [7] [8] 11 To distinguish the role of these two mechanisms we developed an experimental protocol that included an arm in which chemotherapy was administered 24 h before treatment by HIFU and an arm in which chemotherapy was administered concomitantly with HIFU treatment. The chemotherapy used in our experiment was docetaxel for which the half-life is slightly longer than 90 min when administered by i.p. route. 12 The objective of this study was to demonstrate the predominant mechanism of this synergy and in this way determine the best sequence of chemotherapy administration in relation to HIFU treatment for obtaining optimum control of tumoral growth.
Materials and methods

Animals and tumor model
Fischer Copenhagen rats, obtained from Harlan (Indianapolis, IN, USA), were housed in our laboratory. 5 Only male rats, 10-12 weeks old, were used in all experiments. R3327 Dunning prostatic adenocarcinoma subline AT2 was used. Cells were kept in liquid nitrogen. For our experiments, cellular samples of the same pool were warmed and cultured under standard conditions. A rat was given an abdominal s.c. injection of 2 Â 10 6 cells and after 15 days, a solid tumor was obtained, excised and minced; 20-mg pieces were then implanted in the experimental animals and 15 days later, the tumor was ready to be treated (Figure 1a and b) . For the AT2 subline, 7-8 weeks are necessary to induce death.
HIFU treatment
Material and treatment parameters. The prototype device used for treatment consisted of three integrated components.
(1) An ultrasound treatment system located in a tank filled with degassed and deionized water consisting of a spherical transducer with a geometrical focus at 45 mm, an active diameter aperture of 50 mm and a central frequency of 3 MHz. (2) An imaging system consisting of an ultrasound scanner (Combison 311, Kretz, Austria) coupled with a stereotaxic localizing arm. (3) A computer which controlled the firing sequence and the movements of the firing head through a threedimensional positioning system (Microcontrôle, France).
In order to achieve a treatment, multiple shots were made following a spiral model. Each shot was made at an acoustical power of 13 W for 5 s with a 5 s waiting time between shots and were separated by a step of 1.6 mm ( Figure 2 ).
Treatment session
Before treatment the rats were anesthetized with isofluran with the use of a vaporizer (Minerve, Esternay, France). Isofluran is a halogenic volatile anesthetic. Anesthesia induction was done in an induction cage which prepares the animal for the anesthesia (% of isofluran: 3-5% for 2-5 min). Anesthesia maintenance was ensured by the administration of 1.5-2.5 percent of isofluran depending on the animal. Just before the ultrasound shots, the animal received an i.p. fentanyl injection (0.01 mg/kg). Under this anesthesia, the animal was placed on a specially designed Plexiglas gantry with an opening below the abdominal area for the penetration of ultrasound ( Figure 3 ). The tumor was immobilized with a silicone ring fastened to the gantry. This gantry was then mounted on the x-y-z positioning system in order to grossly position the animal over the generator at the approximate focal distance. After the tank was filled with warm (351C) degassed and deionized water, an initial localization of the target area with a 5-MHz ultrasound probe was performed. Using the locating arm of the device, the coordinates of the target volume were sent to the instrument computer which controlled the movements of the therapeutic ultrasound transducer. HIFU-lesion modeling was used to predict the lesion volume under the actual conditions and the number of shots was calculated to cover 75% of the tumor volume. We determined that treating 75% of the tumor volume would allow us to measure the effects of chemotherapy on residual tumor cells outside of the HIFU treatment zone. 13, 14 Programming the computer software produces the appropriate number of shots according to the target volume which was set to 75% of the tumor volume. Synergy between HIFU and docetaxel P Paparel et al Chemotherapy Docetaxel (Aventis pharmaceuticals, Bridgewarer, NJ, USA) was administrated at a dose of 10 mg/kg as a single i.p. injection. The choice of the doses and the protocol of docetaxel administration were made according to an optimal balance of efficacy and tolerance, as previously tested in the litterature. 15 
Experimental design
A total of 15 days after s.c. implantation of the tumor, with the tumor measuring approximately 10 cc, the 52 rats studied were randomized in 4 groups of 13:
(i) Controls, (ii) Group 1: docetaxel alone, (iii) Group 2: HIFU and docetaxel concomitant (docetaxel was administrated 30 min before HIFU treatment) and (iv) Group 3: HIFU and docetaxel administrated 24 h before treatment (docetaxel was administrated 24 h before HIFU treatment).
The tumor volume was measured weekly. Over the course of the observation of tumor growth in the weeks following treatment, the rats were killed if the tumor exceeded 60 mm in diameter or if the tumor volume was such that the rats were no longer able to move. 5 The rats were monitored and fed daily. They were placed in cages in groups of three and all of the cages were located in an air-conditioned area of the animal house approved by the faculty of medicine. Each rat was inspected daily to ensure first of all that it was alive and that good mobility was maintained in the cage despite the tumor. The abdominal wall was also inspected and in case of an abdominal perforation or a tumor with a diameter that surpassed 60 mm, the rat was immediately taken from the cage and euthanized. The experiments were conducted with approval from our Animal care and use committee.
The tumors were photographed upfront and in profile each week following a rule that allowed precise measurement in mm. The formula utilized to calculate tumor volume was length Â width Â height Â 0.5236 (expressed in cm 3 ). 16 
Criteria of evaluation
A rat was considered to be cured if on day 60, the date of the end of the study, there was no trace of tumor on its abdominal wall and no obvious sign of local recurrence. The main judgment criterion for treatment response was the change in tumoral volume and the secondary criterion was the survival of the rats in each group.
Statistical methods
The distributions of the tumor volumes at day 29 of follow-up were globally compared using a nonpara- Synergy between HIFU and docetaxel P Paparel et al metric analysis of variance (Kruskal-Wallis test); then, more specifically, each group was compared to each of the others (Mann-Whitney test) with a Bonferroni correction so as to keep the overall significance level of the comparison tests at Po0.05 (using the correction, one of the six paired test is significant if Po0.0083).
The effects of chemotherapy, HIFU and their interaction on tumor volumes was analyzed using a linear regression for repeated measurements after a logarithmic transformation of the volume values (initially expressed in cm 3 ). To deal with the logarithmic transformation of volume equal to 0, we added 0.5 cm 3 to all volume. The results of this regression analysis were expressed as percentages of volume augmentation per day and as tumor doubling times in days.
All analyses were performed using R 2.0.1 software.
Results
The treatment groups
Overall, 52 rats were used for this study: 13 underwent docetaxel only (group 1), 13 underwent HIFU and docetaxel the same day (group 2), 13 underwent HIFU and a single administration of docetaxel 24 h before treatment (group 3) and 13 were used as controls.
Tumor volume at day 15 of follow-up (day of randomization)
There was no difference in the tumoral volumes between the groups on day 15 (P ¼ 0.37, Kruskal-Wallis test) ( Table 1) .
Tumor volumes at day 29 of follow-up
The distributions of the tumor volumes according to the treatment group were significantly different (Po0.0001) ( Table 1 and Figure 4 ). These volumes were significantly greater in the control group than in group 1 (P ¼ 0.002) and than in groups 2 and 3 (Po0.0001 and P ¼ 0.0001). These volumes were also significantly greater in the group 1 than in groups 2 and 3 (P ¼ 0.0001 and P ¼ 0.0064). There was no difference between the groups 2 and 3 (P ¼ 0.21).
Modification in tumor size
In the whole lot of 52 rats at day 15 of follow-up, the mean tumor volume and the standard deviation were 1.44 and 0.56 cm 3 , respectively. That volume augmented rapidly in three out of the four treatment groups (Table 2): the controls, the group 1 and the group 3. As to the group of rats treated by concomitant HIFU/chemotherapy (group 2), the average augmentation in tumor volume was 1.6 percent per day; however, that augmentation was not significantly different from zero (P ¼ 0.09). The estimations of the average tumor volume augmentation in each treatment group are shown in Table 2 and Figure 5 .
The augmentation of the tumor volume may also be expressed in terms of tumor doubling time. Thus, the tumor doubling times were 7.8 days for the group 1, 43.8 days for the group 2, 16.1 days for the group 3 and 5.9 days for the controls.
The effect of HIFU/chemotherapy on the reduction of the tumor growth was statistically significant (Po0.0001 for group 2 and Po0.0001 for group 3 versus controls), but the tumor growth in group 1 was not statistically different from that in the control group, after Bonferroni correction (P ¼ 0.027 versus controls).
Study of the survival
In the group 2, four rats were cured, one was disapproved on day 44 because of death related to a At day 15, there was no difference in the tumoral volumes between the groups (P ¼ 0.37, Kruskall-Wallis test). At day 29, these volumes were significantly greater in the control group than in group 1 (P ¼ 0.002) and than in groups 2 and 3 (Po0.0001 and P ¼ 0.0001); these volumes were also significantly greater in the group 1 than in groups 2 and 3 (P ¼ 0.0001 and 0.0064); there was no difference between the groups 2 and 3 (P ¼ 0.21). Figure 4 Box plots of tumor volume at day 29 according to treatment group. Synergy between HIFU and docetaxel P Paparel et al perforation of the abdominal wall by necrosis and eight rats were euthanized because tumors exceeded 60 mm in diameter.
In the group 3, four rats were cured, one was disapproved on day 22 because of death related to unknown cause and eight rats were euthanized because tumors exceeded 60 mm in diameter.
In the control group and group 1, all rats were euthanized because tumors exceeded 60 mm in diameter.
Discussion
Docetaxel is a chemotherapy that belongs to the taxan family of drugs developed from paclitaxel. It is a mitotic spindle poison which facilitates in vitro polymerization of tubulin into microtubules and stabilizes microtubules in vivo which results in a blockage of the G 2 /M phase of the cell cycle. 16 An apoptosis inducer, it stimulates the phosphorylation of bcl-2 which is a protein with antiapoptic properties. 12 In addition, docetaxel is used in the clinical setting in patients with hormone refractory prostate cancer. 17, 18 In the group 2, chemotherapy was administered concomitantly with HIFU treatment. The mechanism mentioned to explain the synergy between the two treatments is based on the increase in intracellular penetration of the chemotherapy, thanks to the direct and indirect effects of HIFU: the direct effect concerns the area treated by HIFU (75% of the tumoral volume) where there is an increase in blood flow and in the permeability of the tumor cell membrane thus facilitating the supply and intracellular penetration of docetaxel. 8 The cavitation generated by HIFU takes place with creating a circulating fluid flow ('microstreaming') in the interstitial tissue exposed and inducing shear forces who can created gaps between endothelial cells. 11, 19 The indirect effect that concerns the nontreated tumoral area (25% of the tumoral volume) might be related to the regional hyperthermia caused by the HIFU and the diffusion of the ultrasound beam. 5, 10, 14, 20, 21 At the focal area the temperature of the treated tissue can reach 1001C. 13 The remaining tumoral ring that is nontreated by HIFU is the focus of a rise in temperature that decreases in intensity as one moves further away from the focal area.
14 The hyperthermia in the non treated area might thus facilitate the intracellular penetration of docetaxel. Mohamed et al. 22 demonstrated an in vivo improvement in docetaxel efficacy at 41.51C. Studies have shown that tumor cells were more sensitive to hyperthermia (from 41.5 to 43.51C) than normal cells. 8 Moreover, hyperthermia and docetaxel have a common action since hyperthermia itself favors the disorganization of the microtubular system. 20 In the group 3, chemotherapy was administered 24 h before HIFU treatment. After a single dose peritoneal injection of docetaxel the concentration in peritoneal fluid progressively increases and reaches a plateau from the 90th minute. 12 The molecule then progressively diffuses into the surrounding tissue (colon, stomach, liver, heart) reaching maximum concentration in the anterior abdominal wall from the 90th minute. 12 Dunning tumors implanted subcutaneously in the anterior abdominal wall are therefore completely exposed to the treatment. 12 Docetaxel blocks the cell cycle in the G 2 /M phase. 15, 23 Lokeshwar et al. 16 demonstrated that 80% of all tumor cells are blocked in the G 2 /M phase 24 h after the administration of i.p. paclitaxel in Dunning tumors implanted in Copenhagen rats. In this study the authors demonstrated a potentiation of radiotherapy action by paclitaxel because the effect of radiotherapy is at a maximum on cells in the G 2 /M phase. 16 No data are currently available to ascertain whether treatment with HIFU is at a maximum on cells blocked in the G 2 /M phase; however this mechanism might intervene in this group. Treatment with HIFU acts on tumor cells weakened by chemotherapy. 5, 23 The hyperthermia that is generated by the HIFU is produced 24 h after the administration of docetaxel which has a half-life of a few hours; it therefore has little influence on the intracellular penetration of the chemotherapy in this group.
Our results do not show a statistically significant difference between the two HIFU/chemotherapy groups (groups 2 and 3). The synergy mechanism between HIFU and docetaxel is therefore apparently multifaceted without any absolutely predominant mechanism. The combination of HIFU and docetaxel in the two groups was more efficient than treatment with chemotherapy alone or in the control group. This synergic combination is potentially curative since the rate of total response was higher than 30%. A total of 6 weeks after the application of the different treatments there was no further sign of tumoral progression in these rats. The tumor was entirely necrosed even though only 75% of the tumoral volume was treated. In the group 1, docetaxel slowed down tumoral growth without actually stopping it. Yang et al. 7 cured 12 mice out of 15 with the C1300 neuroblastoma cells, thanks to the combination of HIFU and adriamycin administered concomitantly. This cure rate that is higher than ours is explained by the fact that the entire tumor was treated and not only 75% as was the case in our study.
Our study has a number of limitations. It is not certain whether the results observed with the Dunning model implanted subcutaneously can be adapted to prostatic tumor cells developing in an orthotopic position. We did not administer any corticoids in the rats receiving docetaxel as is done in the clinical setting in order to evaluate only the effects of docetaxel without potentia- Synergy between HIFU and docetaxel P Paparel et al tion by another molecule. 17 Finally, we did not have an HIFU-alone arm because the objective of this study was above all to compare tumoral growth between the two HIFU/docetaxel arms in order to determine the best method of administration of these two treatments.
Conclusion
The mechanism of the synergy between HIFU and docetaxel on the growth of Dunning tumors is apparently multifaceted. More studies are necessary in order to understand all the mechanisms which explain the synergy between these two treatments. The results are encouraging because in the two groups of rats treated with the combination of HIFU and docetaxel the percentage of complete remission was approximately 30%.
